InnoCare Pharma Limited
InnoCare Pharma Limited (INCPF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
incpf · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
InnoCare Pharma LimitedYou INCPF | $3.1B | N/A | — | — |
 ALK-Abelló A/S AKBLF | $6.3B | 42.58x | +56.8% | $5.39 |
 Camurus AB (publ) CAMRF | $3.5B | 49.84x | +83.5% | $12.42 |
 Clicks Group Limited CLCGY | $3.3B | 28.13x | +3.6% | $26.57 |
 COSMOS Pharmaceutical Corporation CSMYF | $3.3B | 16.92x | -37.7% | $390.86 |
 Fielmann AG FLMNY | $4.3B | 18.62x | -31.4% | $0.47 |
 Gedeon Richter PLC GEDSF | $4.7B | 6.89x | -74.6% | $1180.17 |
Industry Average 6 peers with valid PE | — | 27.16x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for InnoCare Pharma Limited (INCPF) measures how much investors pay for each dollar of the company's trailing earnings. INCPF's current PE ratio of N/A is calculated by dividing its stock price of $2.05 by its TTM earnings per share of —.
Frequently asked questions
INCPF pe ratio · 6 questionsINCPF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $2.05 and TTM EPS of —. Data sourced from Financial Modeling Prep via INCPF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · InnoCare Pharma Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09